Clarithromycin
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Clarithromycin: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Clarithromycin is a macrolide antibiotic widely used to treat bacterial infections, including respiratory tract infections, skin and soft tissue infections, and Mycobacterium avium complex (MAC) infections in immunocompromised patients. The TxGNN model predicts it may be effective for Hyperamylasemia, with 0 clinical trials and 1 publication currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (respiratory tract, skin, H. pylori, MAC) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.35% |
| Evidence Level | L4 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmacology, clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit and blocking peptide chain elongation. Beyond its direct antibacterial activity, clarithromycin exhibits clinically relevant immunomodulatory properties — including NF-κB suppression, downregulation of pro-inflammatory cytokines (IL-6, IL-8), and inhibition of matrix metalloproteinases — making it a first-line component of MAC infection treatment regimens.
Hyperamylasemia is a laboratory finding (elevated serum amylase) rather than a primary disease entity. It arises secondarily from conditions such as acute pancreatitis, parotitis, renal failure, and notably, pulmonary MAC/Mycobacterium abscessus infections. The mechanistic link proposed by TxGNN is therefore indirect: clarithromycin may incidentally reduce elevated amylase by treating the underlying mycobacterial infection, rather than targeting amylase production or clearance as a primary pharmacological effect.
The sole supporting publication (PMID 15228140) describes a single case of M. abscessus lung infection complicated by coincidental primary macroamylasemia, where clarithromycin was used as standard MAC therapy. Elevated amylase in that case was an infection complication, not a demonstrated drug target. This represents an incidental association surfaced through knowledge graph traversal, rather than evidence of a clinically meaningful repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15228140 | 2004 | Case Report | Japanese Respiratory Society Journal | M. abscessus pulmonary infection in a 76-year-old male complicated by primary macroamylasemia; clarithromycin was used as part of standard MAC therapy — elevated amylase was an infection complication, not a direct drug target |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction appears to originate from an indirect knowledge graph association — clarithromycin treats MAC infections, and MAC infections can secondarily cause hyperamylasemia — rather than from any direct pharmacological effect on amylase metabolism. With no clinical trials, no prospective studies, and a single case report describing coincidental co-occurrence, there is insufficient biological and clinical rationale to advance this as a standalone repurposing candidate.
To proceed, the following is needed:
- Mechanism of action data (from DrugBank or primary literature) confirming whether clarithromycin has any direct effect on pancreatic or salivary amylase activity
- At least one prospective cohort study or controlled observation demonstrating amylase reduction attributable to clarithromycin independent of infection resolution
- Clarification of the intended therapeutic target: if the goal is to treat MAC-induced hyperamylasemia, this is already covered by the drug's approved antibacterial indication and does not constitute a repurposing opportunity
- New Zealand regulatory pathway assessment once a clinically meaningful indication is established
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.